Biogen Inc. (BIIB): Price and Financial Metrics
BIIB Price/Volume Stats
Current price | $215.63 | 52-week high | $319.76 |
Prev. close | $216.34 | 52-week low | $211.01 |
Day low | $214.00 | Volume | 1,912,200 |
Day high | $217.57 | Avg. volume | 1,181,026 |
50-day MA | $229.64 | Dividend yield | N/A |
200-day MA | $251.96 | Market Cap | 31.34B |
BIIB Stock Price Chart Interactive Chart >
BIIB POWR Grades
- BIIB scores best on the Sentiment dimension, with a Sentiment rank ahead of 88.74% of US stocks.
- The strongest trend for BIIB is in Quality, which has been heading down over the past 26 weeks.
- BIIB's current lowest rank is in the Growth metric (where it is better than 17.29% of US stocks).
BIIB Stock Summary
- BIIB has a market capitalization of $38,170,509,644 -- more than approximately 93.25% of US stocks.
- BIOGEN INC's stock had its IPO on September 17, 1991, making it an older stock than 83.59% of US equities in our set.
- Price to trailing twelve month operating cash flow for BIIB is currently 28.07, higher than 84.95% of US stocks with positive operating cash flow.
- Stocks with similar financial metrics, market capitalization, and price volatility to BIOGEN INC are ON, MCHP, GRMN, TER, and JNPR.
- BIIB's SEC filings can be seen here. And to visit BIOGEN INC's official web site, go to www.biogen.com.
BIIB Valuation Summary
- BIIB's price/sales ratio is 3.8; this is 9.52% lower than that of the median Healthcare stock.
- Over the past 243 months, BIIB's price/sales ratio has gone down 8.8.
Below are key valuation metrics over time for BIIB.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
BIIB | 2023-12-29 | 3.8 | 2.6 | 25.7 | 26.7 |
BIIB | 2023-12-28 | 3.8 | 2.6 | 25.8 | 26.8 |
BIIB | 2023-12-27 | 3.8 | 2.6 | 26.0 | 27.0 |
BIIB | 2023-12-26 | 3.8 | 2.6 | 25.8 | 26.9 |
BIIB | 2023-12-22 | 3.7 | 2.6 | 25.6 | 26.6 |
BIIB | 2023-12-21 | 3.7 | 2.5 | 25.2 | 26.2 |
BIIB Growth Metrics
- Its 5 year revenue growth rate is now at 25.06%.
- The 4 year cash and equivalents growth rate now stands at 180.44%.
- The year over year revenue growth rate now stands at -14.16%.
The table below shows BIIB's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 10,173.4 | 1,384.3 | 3,046.9 |
2022-09-30 | 10,363.2 | 2,397.6 | 2,864.7 |
2022-06-30 | 10,633.6 | 2,541.9 | 2,059.2 |
2022-03-31 | 10,819.5 | 3,032.7 | 1,449.7 |
2021-12-31 | 10,981.7 | 3,639.9 | 1,556.1 |
2021-09-30 | 11,100.5 | 2,434.5 | 1,545.8 |
BIIB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BIIB has a Quality Grade of B, ranking ahead of 87.69% of graded US stocks.
- BIIB's asset turnover comes in at 0.459 -- ranking 97th of 680 Pharmaceutical Products stocks.
- ZSAN, ARMP, and HGEN are the stocks whose asset turnover ratios are most correlated with BIIB.
The table below shows BIIB's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.459 | 0.825 | 0.064 |
2021-06-30 | 0.478 | 0.839 | 0.098 |
2021-03-31 | 0.510 | 0.855 | 0.206 |
2020-12-31 | 0.531 | 0.866 | 0.283 |
2020-09-30 | 0.550 | 0.876 | 0.369 |
2020-06-30 | 0.545 | 0.880 | 0.415 |
BIIB Price Target
For more insight on analysts targets of BIIB, see our BIIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $417.00 | Average Broker Recommendation | 1.64 (Moderate Buy) |
Biogen Inc. (BIIB) Company Bio
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.(Source:Wikipedia)
Latest BIIB News From Around the Web
Below are the latest news stories about BIOGEN INC that investors may wish to consider to help them evaluate BIIB as an investment opportunity.
12 Best Stocks to Buy for an 18 Year OldIn this article, we discuss the 12 best stocks to buy for an 18 year old. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Stocks to Buy for an 18 Year Old. It is an exciting time to be involved in trading stocks. The Federal Reserve in […] |
Healthcare Heroes: 3 Stocks Innovating in Medicine and WellnessDiscover these innovative healthcare stocks, backed by the U.S.'s $4.3 trillion health investment, offering stability and high returns. |
Top 3 Healthcare Stock Picks for the New YearBuy these healthcare stocks for 2024 trading at bargain prices before their earnings inflect higher on improving fundamentals. |
Ionis (IONS), AstraZeneca's Eplontersen Receives FDA NodFDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone. |
Is Eli Lilly Stock A Buy Or A Sell As Shares Seesaw On Recent Obesity Drug Findings?Is Eli Lilly stock a buy or a sell as shares seesaw in the wake of new Zepbound test results? LLY stock a buy or a sell right now? |
BIIB Price Returns
1-mo | -2.76% |
3-mo | -16.67% |
6-mo | -16.10% |
1-year | -21.63% |
3-year | -21.88% |
5-year | -8.78% |
YTD | -16.67% |
2023 | -6.55% |
2022 | 15.42% |
2021 | -2.02% |
2020 | -17.48% |
2019 | -1.39% |
Continue Researching BIIB
Want to see what other sources are saying about Biogen Inc's financials and stock price? Try the links below:Biogen Inc (BIIB) Stock Price | Nasdaq
Biogen Inc (BIIB) Stock Quote, History and News - Yahoo Finance
Biogen Inc (BIIB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...